Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.58 |
| ▸ | CES1 | P23141 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11254948 | 0.85 | CES2 (0.56) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL6026032 | 0.85 | CES2 (0.56) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL15445468 | 0.84 | ELANE (0.47) | CES1ALDH1A1ALOX15GAAMEN1 | |
| SCHEMBL13543200 | 0.83 | CES2 (0.61) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL23313857 | 0.82 | ALB (0.60) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL26054594 | 0.82 | ESR1 (0.49) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL6153221 | 0.80 | RIPK1 (0.51) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL13851527 | 0.80 | CES2 (0.42) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL361933 | 0.80 | CES1 (0.60) | CES2CES1ALDH1A1ALOX15GAA | |
| SCHEMBL29668746 | 0.80 | CES1 (0.60) | CES2CES1ALDH1A1ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215142-B1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2021-03-24 | — | — | EP | disclosed |
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA ONCOLOGY, INC. | 2020-02-13 | — | — | US | disclosed |
| US-10206893-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | FLEXUS BIOSCIENCES INC (US) | 2017-05-25 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598422-B2 | Immunoregulatory agents | FLEXUS BIOSCIENCES, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-09-09 | — | — | US | disclosed |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-1799627-B1 | IRON OR COBALT-CATALYZED CARBON-CARBON COUPLING REACTION OF ARYLS, ALKENES AND ALKINES WITH COPPER REAGENTS | SALTIGO GMBH (DE) | 2010-05-05 | — | — | EP | disclosed |
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-08-13 | — | — | US | disclosed |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ASTRAZENECA AB (SE) | 2009-05-28 | — | — | US | disclosed |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ASTRAZENECA AB | 2009-04-30 | — | — | US | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SALTIGO GMBH (DE) | 2008-10-30 | — | — | US | disclosed |
| WO-2007060408-A2 | L-PHENYLALANINE DERIVATIVES AND THEIR USE AS INTEGRIN ANTAGONISTS | ASTRAZENECA AB (SE) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206893-B2 | Immunoregulatory agents | IDO1, IDO2, INMT | CES2 1199/4885CES1 695/4885ALDH1A1 219/4885 |
| US-20080269514-A1 | Iron or Cobalt-Catalyzed Carbon-Carbon Coupling Reaction of Aryls, Alkenes and Alkines With Copper Reagents | SLC39A14, MAL2, AHR | CES2 691/4885CES1 4028/4885ALDH1A1 874/4885 |
| US-20170143649-A1 | IMMUNOREGULATORY AGENTS | IDO1, IDO2, INMT | CES2 1199/4885CES1 695/4885ALDH1A1 219/4885 |
| US-20090203663-A1 | CHEMICAL COMPOUNDS | ITGB5, ITGB1, ITGA2B | CES2 4620/4885CES1 3218/4885ALDH1A1 565/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | CES2 3002/4885CES1 2002/4885ALDH1A1 4348/4885 |
| US-20090111828-A1 | L-ALANINE DERIVATIVES | ITGA2B, ITGB1, ITGB5 | CES2 4765/4885CES1 2413/4885ALDH1A1 372/4885 |
| US-20100221214-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | EIF2AK2, NSUN2, ZC3HAV1 | CES2 380/4885CES1 161/4885ALDH1A1 287/4885 |
| US-20100228026-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | REN, AGTR2, AGTR1 | CES2 2835/4885CES1 520/4885ALDH1A1 617/4885 |
| US-20200048228-A1 | ALVOCIDIB PRODRUGS AND THEIR USE AS PROTEIN KINASE INHIBITORS | CDK1, CDK2, CDK3 | CES2 4214/4885CES1 2437/4885ALDH1A1 3857/4885 |
| US-20090137601-A1 | L-Phenylalanine Derivatives | ITGB5, ITGB1, ITGA2B | CES2 4813/4885CES1 3413/4885ALDH1A1 1156/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | CES2 417/4885CES1 79/4885ALDH1A1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.